Advanced Filters
noise

Chula Vista, California Clinical Trials

A listing of Chula Vista, California clinical trials actively recruiting patient volunteers.

Found 117 clinical trials

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic dysfunction-associated steatohepatitis (MASH). MASH is a form of metabolic dysfunction-associated steatotic liver disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making …

18 - 75 years of age All Phase 2
R Recruiting Contact

A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects

A Single Center, Single Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

18 - 70 years of age All Phase 1
S Sara Gorczynski, DPT

Evaluating the Effectiveness of Clinical Practice Guideline Adherence for Patellofemoral Pain

The overall goal of this multisite, randomized clinical trial is to evaluate the short- and long-term effectiveness of a Clinical Practice Guideline (CPG)-adherent physical therapy approach to patellofemoral pain (PFP) management among military Service members. The main questions it aims to answer are: Can a CPG-adherent care approach to PFP …

18 years of age All Phase N/A
A ASCEND-IBD Trial Center

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

19 - 55 years of age All Phase 1
R Rita Mehta, MD

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. …

18 years of age All Phase 2
A ASCEND-IBD Trial Center

A First-in-Human Single and Multiple Ascending Dose Study of MT-251

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants

19 - 55 years of age All Phase 1
A ASCEND-IBD Trial Center

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.

19 - 55 years of age All Phase 1

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

18 years of age All Phase 1
C Chuchu Li

Language Control Across Modalities

This study aims to investigate how unimodal bilinguals who speak two languages and bimodal bilinguals who speak one language and sign another control languages across comprehension and production. Participants will complete different language tasks (e.g., classify a word, name a picture) in different languages, and their behavioral performance will be …

18 - 65 years of age All Phase N/A
R Rita Mehta, MD

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence …

18 - 60 years of age Female Phase 3

Simplify language using AI